American Physicians Service Group Inc 2018 Q2 Big Money Sentiment Better Than Expected: at 1.11

Positions for American Physicians Service Group Inc (NASDAQ:AMPH)

“Big money sentiment for American Physicians Service Group Inc (NASDAQ:AMPH) in Q2 2018 decreased to 1.11, SEC filings reveal. That’s down -0.34, from 2018Q1’s 1.45. 50 funds opened new and increased positions, while 45 sold and decreased their stakes in American Physicians Service Group Inc so the sentiment has dropped. These funds own 19.80 million shares, that’s down from 20.28 million shares in 2018Q1. Funds holding American Physicians Service Group Inc in top 10 changed to 0 from 0 for the same number . 11 Investors Sold All; 34 Reduced Holdings; 35 increased holdings while 15 funds bought holdings.

Biggest American Physicians Service Group Inc Investors

Cortina Asset Management Llc owns 392,296 shares in American Physicians Service Group Inc as of Q2 2018. American Physicians Service Group Inc’s shareholder Argent Capital Management Llc owns 235,775 shares as of Q2 2018. Furthermore, Federated Investors Inc Pa reported 1.28 million shares in American Physicians Service Group Inc equivalent to 0.06% of its US equity exposure. The New York-based fund Rothschild Asset Management Inc have invested about 0.05% of the active investment manager’s stock portfolio in American Physicians Service Group Inc. The New York-based fund Engineers Gate Manager Lp holds 25,333 shares or 0.03% of their US equity exposure.

Amphastar Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development, manufacture, marketing, and sale of generic and proprietary injectable, inhalation, and intranasal products.The firm is worth $1.01 billion. It operates in two divisions, Finished Pharmaceutical Products and Active Pharmaceutical Ingredients.Currently it has negative earnings. The companyÂ’s product portfolio comprises enoxaparin, a low molecular weight heparin that is used as an anticoagulant for prevention and treatment of deep vein thrombosis; naloxone for treating opioid overdose; Cortrosyn, a lyophilized powder for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency; Amphadase, a bovine-sourced hyaluronidase injection for the dispersion and absorption of other injected drugs; and lidocaine jelly, a local anesthetic product for urological procedures.

Ticker’s shares touched $21.99 during the last trading session after 1.24% change.Amphastar Pharmaceuticals, Inc. has 248,433 shares volume, 15.61% up from normal. AMPH is uptrending and has moved 17.25% since December 8, 2017. The stock outperformed the S&P500 by 1.63%.

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)’s quarterly earnings will be revealed on March, 11., according to RTT. Analysts have expectation on stock’s earnings per share of $0.11. That’s up 10.00 % from last year’s $0.1 earnings per share. AMPH’s profit could be $5.07 million if the current earnings per share of $0.11 is accurate. After $0.12 EPS report last quarter, Wall Street now forecasts -8.33 % negative EPS growth of Amphastar Pharmaceuticals, Inc..

Kbc Group Nv owns 63,871 shs. Pinnacle Financial Prtnrs owns 1,000 shs. Sg Americas holds 10,544 shs. Credit Suisse Ag reported 47,844 shs. City Holdg holds 0% or 400 shs. Great West Life Assurance Can reported 43,863 shs. Tci Wealth Advsr owns 287 shs or 0% of their US capital. Bluestein R H & Com accumulated 15,000 shs or 0.01% of the stock. Dimensional Fund Advsr L P stated it has 1.77 million shs. 89,343 were reported by Rhumbline Advisers. Barclays Public Limited Company invested in 0% or 18,289 shs. Comml Bank Of America De has 0% invested in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) for 12,661 shs. 735 are owned by Pnc Fin Grp. Piedmont Investment Advsr Ltd Company holds 0.01% in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) or 8,358 shs. Legal & General Gru Pcl invested in 71,656 shs or 0% of the stock.

For more Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) news released briefly go to: Globenewswire.com, Zacks.com, Seekingalpha.com, Seekingalpha.com or Nasdaq.com. The titles are as follows: “Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2018 – GlobeNewswire” released on May 09, 2018, “MNK or AMPH: Which Is the Better Value Stock Right Now? – Zacks.com” on October 02, 2018, “Apple suppliers, chips drop on Cirrus cut – Seeking Alpha” with a publish date: December 04, 2018, “Does Amphastar’s Pipeline Warrant Its Valuation? – Seeking Alpha” and the last “New Research Coverage Highlights Phibro Animal Health, RadNet, Amphastar Pharmaceuticals, FibroGen, Sientra, and Flexion Therapeutics — Consolidated Revenues, Company Growth, and Expectations for 2018 – Nasdaq” with publication date: November 27, 2018.

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.